The FDA adverse-event record for other canids

Other Canids Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 42 adverse event reports for Other Canids, distributed across 3 distinct breeds currently tracked in the system. Of those reports, 2 involved a death outcome, producing a 4.8% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Other Canids are Vomiting (11 reports), Lethargy (see also Central nervous system depression in 'Neurological') (5 reports), Emesis (4 reports), Lack of efficacy (endoparasite) - heartworm (4 reports), with Vomiting leading the reaction traffic at 11 submissions. On the product side, Milbemycin Oxime + Spinosad is the single most-referenced drug with 7 reports, followed by Spinosad (6), Ivermectin + Pyrantel As Pamoate Salt (5), Ivermectin/Pyrantel Pamoate Chewable 272Mcg/652Mg (3). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Other Canids reporting patterns against other companion animals in the dataset.

Of the 42 Other Canids reports with a coded outcome, Recovered/Normal accounts for the largest share at 42.9%. Annual submission volume spans 2,011 to 2,025 reports across the 14 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 3 tracked other canids breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.